US FDA Doesn’t Need Conditional Approval Pathway, Cavazzoni Tells House Committee

CDER director says agency has many tools to expedite development and does not endorse adding a pathway similar to EU’s conditional approval. Neurodegenerative diseases hearing in Energy & Commerce Committee focuses more on ALS than Aduhelm.

CDER Director Patrizia Cavazzoni answers questions virtually on drug development in neurodegenerative diseases during a House Energy and Commerce Health Subcommittee hearing. • Source: screenshot

Rather than creating another expedited pathway, Patrizia Cavazzoni suggested to members of Congress that the key to speeding development in neurodegenerative diseases is a better scientific understanding of the conditions.

During a 29 July House Energy and Commerce Health Subcommittee hearing on advancing treatments for neurodegenerative diseases, Chair Anna Eshoo,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet